Abstract:Heart failure (HF) as a result of myocardial infarction (MI) is a major cause of fatality worldwide. However, the cause of cardiac dysfunction succeeding MI has not been elucidated at a sarcomeric level. Thus, studying the alterations within the sarcomere is necessary to gain insights on the fundamental mechansims leading to HF and potentially uncover appropriate therapeutic targets. Since existing research portrays regulatory light chains (RLC) to be mediators of cardiac muscle contraction in both human and animal models, its role was further explored In this study, a detailed characterisation of the physiological changes (i.e., isometric force, calcium sensitivity and sarcomeric protein phosphorylation) was assessed in an MI mouse model, between 2D (2 days) and 28D post-MI, and the changes were related to the phosphorylation status of RLCs. MI mouse models were created via complete ligation of left anterior descending (LAD) coronary artery. Left ventricular (LV) papillary muscles were isolated and permeabilised for isometric force and Ca2+ sensitivity measurement, while the LV myocardium was used to assay sarcomeric proteins' (RLC, troponin I (TnI) and myosin binding protein-C (MyBP-C)) phosphorylation levels and enzyme (myosin light chain kinase (MLCK), zipper interacting protein kinase (ZIPK) and myosin phosphatase target subunit 2 (MYPT2)) expression levels. Finally, the potential for improving the contractility of diseased cardiac papillary fibres via the enhancement of RLC phosphorylation levels was investigated by employing RLC exchange methods, in vitro. RLC phosphorylation and isometric force potentiation were enhanced in the compensatory phase and decreased in the decompensatory phase of HF failure progression, respectively. There was no significant time-lag between the changes in RLC phosphorylation and isometric force during HF progression, suggesting that changes in RLC phosphorylation immediately affect force generation. Additionally, the in vitro increase in RLC phosphorylation levels in 14D post-MI muscle segments (decompensatory stage) enhanced its force of isometric contraction, substantiating its potential in HF treatment. Longitudinal observation unveils potential mechanisms involving MyBP-C and key enzymes regulating RLC phosphorylation, such as MLCK and MYPT2 (subunit of MLCP), during HF progression. This study primarily demonstrates that RLC phosphorylation is a key sarcomeric protein modification modulating cardiac function. This substantiates the possibility of using RLCs and their associated enzymes to treat HF.

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

Alteration of mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated heart failure with preserved ejection fraction.

Theoretical Investigation Of The Mechanism Of Heart Failure Using A Canine Ventricular Cell Model: Especially The Role Of Up-Regulated Camkii And Sr Ca2+ Leak

Activating Cardiac Myosin, a Novel Inotropic Mechanism to Improve Cardiac Function in Conscious Dogs with Congestive Heart Failure

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Autologous Skeletal Myoblast Transplantation Improved Hemodynamics and Left Ventricular Function in Chronic Heart Failure Dogs.

Danicamtiv reduces myosin's working stroke but enhances contraction by activating the thin filament

Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle

Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future

Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases

Cardiac myosin inhibitor, CK-586, minimally reduces systolic function and ameliorates obstruction in feline hypertrophic cardiomyopathy

Improved Left Ventricular Function in Chronic Heart Failure Dogs by Skeletal Autologous Myoblast Transplantation

Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.

Myosin Isoform-Dependent Effect of Omecamtiv Mecarbil on the Regulation of Force Generation in Human Cardiac Muscle

Autologous Skeletal Myoblast Transplantation Improves Hemodynamics Dogs with Chronic Heart Failure Dogs

Protective Effects of Cardiac Resynchronization Therapy in a Canine Model with Experimental Heart Failure by Improving Mitochondrial Function: a Mitochondrial Proteomics Study

Chronic Therapy with a Partial Adenosine A1-Receptor Agonist Improves Left Ventricular Function and Remodeling in Dogs with Advanced Heart Failure

Functional and Molecular Characterisation of Heart Failure Progression in Mice and the Role of Myosin Regulatory Light Chains in the Recovery of Cardiac Muscle Function

Abstract 281: Long-Term Therapy with a Partial Adenosine A1-Receptor Agonist Upregulates Mrna and Protein Expression of Glucose Transporters in Left Ventricular Myocardium of Dogs with Chronic Heart Failure

Overexpression of sarcoplasmic reticulum calcium ATPase induced hemodynamic and proteomic changes in a dog model of heart failure